请输入关键字
请输入关键字
订购
*国家
中国
美国
中国香港
中国澳门
中国台湾
阿尔巴尼亚
阿尔及利亚
阿根廷
阿拉伯联合酋长国
阿鲁巴
阿曼
阿塞拜疆
阿森松岛
埃及
埃塞俄比亚
爱尔兰
爱沙尼亚
安道尔
安哥拉
安圭拉
安提瓜和巴布达
奥地利
奥兰群岛
澳大利亚
巴巴多斯
巴布亚新几内亚
巴哈马
巴基斯坦
巴拉圭
巴勒斯坦领土
巴林
巴拿马
巴西
白俄罗斯
百慕大
保加利亚
北马里亚纳群岛
贝宁
比利时
冰岛
波多黎各
波兰
波斯尼亚和黑塞哥维那
玻利维亚
伯利兹
博茨瓦纳
不丹
布基纳法索
布隆迪
朝鲜
赤道几内亚
丹麦
德国
迪戈加西亚岛
东帝汶
多哥
多米尼加共和国
多米尼克
俄罗斯
厄瓜多尔
厄立特里亚
法国
法罗群岛
法属波利尼西亚
法属圭亚那
法属南部领地
梵蒂冈
菲律宾
斐济
芬兰
佛得角
福克兰群岛
冈比亚
刚果(布)
刚果(金)
哥伦比亚
哥斯达黎加
格恩西岛
格林纳达
格陵兰
格鲁吉亚
古巴
瓜德罗普
关岛
圭亚那
哈萨克斯坦
海地
韩国
荷兰
荷属加勒比区
荷属圣马丁
黑山
洪都拉斯
基里巴斯
吉布提
吉尔吉斯斯坦
几内亚
几内亚比绍
加拿大
加纳
加纳利群岛
加蓬
柬埔寨
捷克
津巴布韦
喀麦隆
卡塔尔
开曼群岛
科科斯(基林)群岛
科摩罗
科索沃
科特迪瓦
科威特
克罗地亚
肯尼亚
库克群岛
库拉索
拉脱维亚
莱索托
老挝
黎巴嫩
立陶宛
利比里亚
利比亚
联合国
列支敦士登
留尼汪
卢森堡
卢旺达
罗马尼亚
马达加斯加
马恩岛
马尔代夫
马耳他
马拉维
马来西亚
马里
马其顿
马绍尔群岛
马提尼克
马约特
毛里求斯
毛里塔尼亚
美国本土外小岛屿
美属萨摩亚
美属维尔京群岛
蒙古
蒙特塞拉特
孟加拉国
秘鲁
密克罗尼西亚
缅甸
摩尔多瓦
摩洛哥
摩纳哥
莫桑比克
墨西哥
纳米比亚
南非
南极洲
南乔治亚和南桑威奇群岛
南苏丹
瑙鲁
尼加拉瓜
尼泊尔
尼日尔
尼日利亚
纽埃
挪威
诺福克岛
帕劳
皮特凯恩群岛
葡萄牙
日本
瑞典
瑞士
萨尔瓦多
萨摩亚
塞尔维亚
塞拉利昂
塞内加尔
塞浦路斯
塞舌尔
沙特阿拉伯
圣巴泰勒米
圣诞岛
圣多美和普林西比
圣赫勒拿
圣基茨和尼维斯
圣卢西亚
圣马丁岛
圣马力诺
圣皮埃尔和密克隆群岛
圣文森特和格林纳丁斯
斯里兰卡
斯洛伐克
斯洛文尼亚
斯瓦尔巴和扬马延
斯威士兰
苏丹
苏里南
所罗门群岛
索马里
塔吉克斯坦
泰国
坦桑尼亚
汤加
特克斯和凯科斯群岛
特里斯坦-达库尼亚群岛
特立尼达和多巴哥
突尼斯
图瓦卢
土耳其
土库曼斯坦
托克劳
瓦利斯和富图纳
瓦努阿图
危地马拉
委内瑞拉
文莱
乌干达
乌克兰
乌拉圭
乌兹别克斯坦
希腊
西班牙
西撒哈拉
新加坡
新喀里多尼亚
新西兰
匈牙利
休达及梅利利亚
叙利亚
牙买加
亚美尼亚
也门
伊拉克
伊朗
以色列
意大利
印度
印度尼西亚
英国
英属维尔京群岛
英属印度洋领地
约旦
越南
赞比亚
泽西岛
乍得
直布罗陀
智利
中非共和国
*省份
*城市
*姓名
*电话
*单位
*职位
*邮箱
*请输入验证码
*验证码
B-hCD3E mice
Strain Name C57BL/6-Cd3etm2(hCD3E)/Bcgen Common Name  B-hCD3E mice
Background C57BL/6 Catalog number  110008
Related Genes 
CD3E (CD3E molecule)
NCBI Gene ID
12501

Protein expression analysis


from clipboard


Strain specific CD3E expression analysis in homozygous B-hCD3E mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hCD3E mice, and analyzed by flow cytometry with species-specific anti-CD3E antibody. Mouse CD3E was exclusively detectable in WT mice. Human CD3E were exclusively detectable in homozygous B-hCD3E but not WT mice.


Phenotypic analysis 


from clipboard


Thymus and spleen were isolated and weighed from C57BL/6 and B-hCD3E mice (n=6). There was no significant difference in spleen weight between C57BL/6 and B-hCD3E mice. However, the thymus weight in B-hCD3E mice is slightly lower than that of WT C57BL/6 mice.


Analysis of leukocytes subpopulation in B-hCD3E mice


from clipboard



Analysis of leukocytes subpopulation in B-hCD3E mice - Thymus
Thymocytes were isolated from 8-week-old C57BL/6 and B-hCD3E mice (n=6). The proportion of leukocytes subpopulation was tested by flow cytometry. As a result, the expression profile of leukocytes subpopulation in homozygous B-hCD3E mice is similar to that in the C57BL/6 mice, indicating that differentiation of T, B, NK, Monocyte, DC and macrophage cells are not affected by the humanization of hCD3E.



Analysis of leukocytes subpopulation in B-hCD3E mice

from clipboard


from clipboard



Analysis of T cell subpopulation in B-hCD3E mice – Thymus
The lymphocytes were isolated from thymus in 8-week-old C57BL/6 and B-hCD3E mice (n=6). The proportion of T cells subpopulation was tested by flow cytometry. As a result, the expression profile of lymphocyte subpopulation in homozygous B-hCD3E mice is similar to that in the C57BL/6 mice, indicating that T cell differentiation is not affected by the humanization of hCD3E.



Analysis of thymus lymphocyte subpopulation in B-hCD3E mice

from clipboard

Thymocytes were isolated from 4-week-old C57BL/6 and B-hCD3E mice (n=4). A. Representative FACS plots. Single live CD45+ cells were gated for CD3 T cell population and used for further analysis as shown here. B. Results of FACS analysis. The Percentage of CD4, CD8 T cells in B-hCD3E mice was similar to that of C57BL/6 mice, indicating that T cell subpopulation in thymus of B-hCD3E mice was not significantly affected by Cd3e gene humanization.


Analysis of leukocytes subpopulation in B-hCD3E mice


from clipboard

from clipboard


Analysis of leukocytes subpopulation in B-hCD3E mice -spleen
Splenocytes were isolated from 8-week-old C57BL/6 and B-hCD3E mice (n=6). The proportion of leukocytes subpopulation was tested by flow cytometry. As a result, the expression profile of leukocytes subpopulation in homozygous B-hCD3E mice is similar to that in the C57BL/6 mice, indicating that differentiation of T, B, NK, Monocyte, DC and macrophage cells are not affected by the humanization of hCD3E.


Analysis of leukocytes subpopulation in B-hCD3E mice



from clipboard

from clipboard


Analysis of T cell subpopulation in B-hCD3E mice – spleen.
The lymphocytes were isolated from spleen in 8-week-old C57BL/6 and B-hCD3E mice (n=6). The proportion of T cells subpopulation was tested by flow cytometry. As a result, the expression profile of lymphocyte subpopulation in homozygous B-hCD3E mice is similar to that in the C57BL/6 mice, indicating that T cell differentiation is not affected by the humanization of hCD3E.



Analysis of spleen lymphocyte subpopulation in B-hCD3E mice


from clipboard


Analysis of lymphocyte subpopulations by FACS.

The lymphocyte were isolated from C57BL/6 and B-hCD3E mice (n=4). Single live cells were gated for CD45 population and used for further analysis as indicated here. Percent of T cell , B cell and Treg cell in homozygous B-hCD3E mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hCD3E in place of its mouse counterpart does not change the overall development, differentiation or distribution of these cell types in spleen.


Analysis of B and T cell subpopulation by FACS – Spleen, PBMC, Lymph node


from clipboard

Lymphocytes were isolated from spleen, peripheral blood and lymph node of C57BL/6 and B-hCD3E mice (n=4). Flow cytometry analysis was performed to assess Lymphocytes subpopulations. Single live cells were gated for CD45 population and used for further analysis as shown here. The Percentage of T, B, cells in B-hCD3E mice was similar to that of C57BL/6 mice.


Analysis of T cell activation stimulated with anti-CD3 antibody in vitro


from clipboard


T cells (2.5×106) were isolated from splenocytes of C57BL/6 and B-hCD3E mice (n=4), and were incubated in the presence of anti-CD3E antibody (2ug/ml) and anti-mCD28 antibody (5ug/ml) for 48h. T cell proliferation was tested by flow cytometry. T cell activation in B-hCD3E mice was significantly up-regulated by anti-hCD3E antibody, similar to the activation level shown in C57BL/6 mice treated with anti-mCD3E antibody.


Analysis of T cell activation stimulated with anti-CD3 antibody in vitro


from clipboard


T cells (2.5×106) were isolated from the splenocytes of C57BL/6 and B-hCD3E mice (n=4), and incubated in the presence of anti-CD3E antibody (2ug/ml) and anti-mCD28 (5ug/ml) for 24h, 48h and 72h. T cell proliferation was measured by flow cytometry. T cell activation in B-hCD3E mice was significantly up-regulated by anti-hCD3 antibody, similar to the activation level shown in the anti-mCD3 antibody-treated C57BL/6 mice, indicating that Cd3e humanization in B-hCD3E mice does not affect T cell activation in spleen.


Analysis of T cell activation stimulated with anti-CD3 antibody in vitro

from clipboard


T cells (2.5×106) were isolated from the splenocytes of C57BL/6 and B-hCD3E mice (n=4), and incubated in the presence of anti-CD3E antibody (2ug/ml)  and anti-mCD28 antibody (5ug/ml) for 24h, 48h and 72h. IFN-γ and IL-2 production were tested using ELISA method. Concentration of IFN-γ and IL-2 in B-hCD3E mice was similar to that of C57BL/6 mice, indicating that Cd3e humanization in B-hCD3E mice does not affect T cell activation in spleen.


Analysis of T cell activation stimulated with anti-CD3 antibody ex vivo


from clipboard


C57BL/6 and B-hCD3E mice were injected intraperitoneally with anti-CD3E antibody (10ug/mouse). After 24h, T cells were isolated from splenocytes of C57BL/6 and B-hCD3E mice (n=4). T cell proliferation was measured by flow cytometry. T cell activation in B-hCD3E mice was significantly up-regulated by anti-hCD3E antibody, similar to the activation level in the anti-mCD3E antibody-treated C57BL/6 mice, demonstrating that introduction of hCD3E in place of its mouse counterpart does not affect T cell activation in spleen.


Analysis of T cell activation stimulated with anti-CD3 antibody ex vivo

from clipboard


C57BL/6 and B-hCD3E mice were injected intraperitoneally with anti-CD3E antibody (10ug/mouse). After 48h, T cells were isolated from splenocytes of C57BL/6 and B-hCD3E mice (n=4). T cell proliferation was measured by flow cytometry. T cell activation in B-hCD3E mice was significantly down-regulated, similar to the activation level in the anti-mCD3 antibody-treated C57BL/6 mice, demonstrating that introduction of hCD3E in place of its mouse counterpart does not affect T cell activation in spleen.


Cytotoxicity evaluation of CD3-PD-L1 bispecific antibody in vitro 

from clipboard


B-hCD3E mouse spleen cells were mixed with MC38-hPD-L1 and various concentrations of CD3-PD-L1 bispecific antibodies were added. The killing activity was detected after 48 hours. When effector cells : target  cells (E:T) =10:1,the EC50 of CD3-PD-L1 bispecific antibodies activity was 452.4 ng/mL; When E:T=20:1,the EC50 of CD3-PD-L1 bispecific antibodies activity was 144.2 ng/mL


Blood routine test in B-hCD3E mice


from clipboard


Complete blood count (CBC). Blood from female C57BL/6 and B-hCD3E mice (n=8, 7 week-old) were collected and analyzed for CBC. There was no differences among any measurement between C57BL/6 and B-hCD3E mice, indicating that introduction of hCD3E in place of its mouse counterpart does not change blood cell composition and morphology. Values are expressed as mean ± SEM.

Blood chemistry of B-hCD3E mice

from clipboard


Blood chemistry tests of B-hCD3E mice. Serum from female C57BL/6 and B-hCD3E mice (n=8, 7week-old) were collected and analyzed for levels of ALT (alanine aminotransferase) and AST (aspartate aminotransferase). The measurement results were similar between C57BL/6 and B-hCD3E mice, indicating that introduction of hCD3E in place of its mouse counterpart does not change ALT and AST levels or health of liver. Values are expressed as mean ± SEM.




CD3 Abs efficacy evaluation 


from clipboard

Murine colon cancer MC38 cells were subcutaneously implanted into C57BL/6 (A) and B-hCD3E (B) mice. Mice were grouped when the tumor size was approximately 150±50mm3 (n=5).In B-hCD3E mice, mPD-1 antibody significantly inhibited tumor growth, indicating their T cells function normally. However, in B-hCD3E mice, tumor growth was faster after anti-hCD3E antibody treatment, which may be caused by activation induced cell death (AICD). As a result, the B-hCD3E mouse model is a powerful tool for in vivo CD3 antibody pharmacological efficacy studies.


T cell activation in CD3 Abs efficacy evaluation


from clipboard

the proportion of T cells was significantly decreased due to the activation induced cell death (AICD) effect caused by CD3E antibody treatment. However, the proportion of T cells has no significant change in the anti-mPD-1 antibody group. (A) Compared with hlgG Ab , there is no significant difference in the percentage of CD19+ cells in total CD45+ cells after hCD3 Ab or mCD3 Ab treatment. (B) Compared with hlgG Ab, the percentage of TCR-β positive cells was significantly decreased after treatment with hCD3 Ab in the humanized mice.


Percentage of CD4+ and CD8+ cells after hCD3 antibody treatment

from clipboard


(A) Compared with hlgG Ab, the percentage of CD4+ T cells in the blood decreased significantly after hCD3E Ab treatment. (B) Compared with hlgG Ab, the percentage of CD8+ T cells in the blood was significantly reduced after hCD3E Ab treatment. 


hCD3 Abs efficacy evaluation with two doses

from clipboard

Murine colon cancer MC38 cells were subcutaneously implanted into B-hCD3E mice. Mice were divided into control and treatment groups(n=5) when tumon size was approximately 150±50 mm3. High doses of hCD3E antibodies resulted in faster tumor growth due to activation induced cell death (AICD), confirming that the B-hCD3E mouse model is a powerful tool for in vivo anti-hCD3 antibody pharmacological efficacy study. (A) Tumor average volume ±SEM, (B) Mice average weight±SEM.


Dose-dependent T cell depletion caused by hCD3 Ab treatment

from clipboard


The ratio of B and T cells in the blood was detected by flow cytometry. Lymphocytes were isolated from peripheral blood at the end of the experiment. In the treatment group, the proportion of T cells was significantly reduced due to the activation induced cell death (AICD) effect caused by CD3E antibody treatment.

Tumor marker Ab (X) efficacy evaluation with two doses

from clipboard


Antitumor activity of Antibody X in B-hCD3E mice. (A) High-dose Antibody X inhibited MC38 tumor growth in B-hCD3E mice(n=5). Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hCD3E mice. Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with Antibody X with doses and schedules indicated in panel ; (B) Body weight changes during treatment. As shown in panel A, high-dose Antibody X were efficacious in controlling tumor growth in B-hCD3E mice, demonstrating that the B-hCD3E mice provide a powerful preclinical model for in vivo evaluation of Antibody X . Values are expressed as mean ±SEM


T cell activation in tumor marker Ab (X) efficacy evaluation with two doses

from clipboard


The ratio of B and T cells in the blood of mice was detected by flow cytometry. Lymphocytes were isolated from peripheral blood at the experimental end point. In the treatment group, the ratio of B and T cells did not change significantly. 


Blinatumomab efficacy evaluation

from clipboard


MC38-hCD19 cells were  implanted subcutaneously into B-hCD3E mice. The mice were divided into control and treatment groups (n=6) when the tumor size was about 150±50 mm3. High-dose hCD3E antibody (Blinatumomab) significantly inhibited tumor growth, confirming that the B-hCD3E mouse model is a powerful tool for evaluating the efficacy of bispecific antibody against hCD3E in vivo.(A) Tumor average volume ± SEM, (B) Mice average weight ±SEM.

CD3E BsAb Efficacy Evaluation 


from clipboard

Antitumor activity of CD3E BsAb in B-hCD3E mice. (A) CD3E BsAb inhibited tumor growth in B-hCD3E mice. (B) Body weight changes during treatment. As shown in panel A, CD3E BsAb with different doses were efficacious in controlling tumor growth in B-hCD3E mice, demonstrating that the B-hCD3E mice provide a powerful preclinical model for in vivo evaluation of CD3E BsAb. Values are expressed as mean ± SEM.


CD3-hEpCAM BsAb efficacy evaluation

from clipboard



MC38-hEpCAM cells were implanted subcutaneously into B-hCD3E mice. The mice were divided into control and treatment groups when the tumor size was about 100±20 mm3. The results show that the anti-hCD3E/hEpCAM bispecific antibody has a moderate degree of antitumor activity compared to the control group. The data also show that anti-mouse CD4 (a CD4-depleting antibody) enhances the antitumor activity of the bispecific anti-hCD3E/hEpCAM antibody.